## 1. Phylogeny

Proto‐oncogene tyrosine‐protein kinase Src (commonly referred to as c‐Src or pp60c‐src) belongs to the Src family kinases (SFKs), a subgroup of non‐receptor tyrosine kinases that form one of the major classes of protein kinases within the human kinome. Phylogenetic analyses have revealed that the catalytic core of Src, along with its key regulatory domains, is evolutionarily ancient and highly conserved. Orthologs of Src exist not only in all mammalian species but also in early diverging metazoans and even in some unicellular eukaryotes, suggesting that the fundamental role of Src in cell signaling was already established in the Last Eukaryotic Common Ancestor (LECA) (agius2019selectiveproteolysisto pages 7-8, bradley2019evolutionofprotein pages 1-2). Within the human kinome, Src is classified under the tyrosine kinase (TK) group. It possesses a high degree of sequence homology with other SFK members such as Fyn, Yes, Lyn, Lck, Hck, Fgr, and Blk, which explains why many of their substrate specificities and regulatory mechanisms overlap. Despite this apparent redundancy, Src is frequently cited as the primary kinase activated following receptor engagement across multiple pathways and cell types, and it participates in both shared and unique regulatory functions (amatya2019dynamicregulatoryfeatures pages 7-9, li2022srcfamilykinases pages 1-2). Comparative studies have shown that while the overall domain architecture is conserved among SFKs, subtle variations in the “unique” domain and in the regulatory sequences contribute to differences in their cellular localization and interaction partners. Such details not only underpin functional specialization but also indicate that Src emerged early in kinase evolution and continues to be subjected to strong evolutionary constraints that preserve its critical role in signal transduction.

## 2. Reaction Catalyzed

Src catalyzes the reversible transfer of the γ-phosphate group from adenosine triphosphate (ATP) to a specific hydroxyl group on the aromatic ring of a tyrosine residue in a protein substrate. Chemically, this reaction can be represented as:  
  ATP + protein-(L-tyrosine) → ADP + protein-(phospho-L-tyrosine) + H⁺.  
This classical phosphorylation reaction is central to the regulation of protein function; by adding a phosphate group, Src alters the conformation, subcellular localization, and interaction affinity of its substrates. In the cellular context, receptor clustering or dimerization following ligand binding (to immune receptors, integrins, receptor tyrosine kinases, G protein-coupled receptors, or cytokine receptors) results in the recruitment of Src to these receptor complexes. Once localized at the membrane, Src phosphorylates tyrosine residues within the cytoplasmic domains of receptors as well as a host of downstream signaling proteins, thereby initiating or modulating an array of signaling cascades. This post-translational modification serves as a binary “on-off” switch for protein activity and interactions, and it is crucial for regulating processes such as gene transcription, actin cytoskeletal rearrangements, cell cycle progression, apoptotic regulation, and cellular transformation (mohanty2016hydrophobiccorevariations pages 21-23, chakraborty2019targetingdynamicatpbinding pages 9-10).

## 3. Cofactor Requirements

The kinase activity of Src relies on the presence of divalent metal ions to properly coordinate nucleotide binding and catalysis. Magnesium ions (Mg²⁺) are required as the principal cofactor; they bind to ATP in the active site, stabilize the transition state, and ultimately facilitate the phosphoryl transfer to the tyrosine residue on the target protein. While manganese (Mn²⁺) can in some cases substitute for magnesium in biochemical assays, physiological Src activity is predominantly supported by Mg²⁺ (cabail2016autothiophosphorylationactivityof pages 10-10, li2022srcfamilykinases pages 1-2). In addition to metal ion cofactors, Src’s activity is modulated by a lipid-based regulatory mechanism: the N-terminal region of Src undergoes N-myristoylation, a post-translational modification in which a myristate group is covalently attached to the glycine residue at the extreme N-terminus. Although N-myristoylation is not considered a classical enzymatic cofactor, it is critical for anchoring Src to cellular membranes. This membrane association is essential for bringing Src into close proximity with receptor complexes and downstream substrates, thus indirectly contributing to optimal catalytic activity (chakraborty2019targetingdynamicatpbinding pages 9-10).

## 4. Substrate Specificity

Src displays broad substrate specificity that reflects its pivotal role in mediating diverse signal transduction events. Its catalytic activity is largely directed toward accessible tyrosine residues on proteins involved in processes such as cell adhesion, migration, proliferation, and differentiation. The enzyme does not have a strict linear consensus sequence like some serine/threonine kinases; rather, its specificity is defined by both the immediate amino acid sequence surrounding the tyrosine residue and by the three-dimensional structure of the substrate which determines accessibility to the Src catalytic cleft.

Among the best‐characterized substrates of Src are focal adhesion proteins, including focal adhesion kinase (PTK2/FAK1) and paxillin (PXN). Phosphorylation of these proteins links signals from integrin-mediated adhesion to the reorganization of the actin cytoskeleton, which is fundamental for cell mobility and dynamic changes at the cell–matrix interface (amatya2019dynamicregulatoryfeatures pages 7-9, gormal2024locationlocationlocation pages 18-19). Similarly, Src phosphorylates components of cell–cell junctions such as beta-catenin (CTNNB1), delta-catenin (CTNND1), and plakoglobin (JUP) that are essential for adherens junction stability, as well as gap junction proteins like connexin-43 (GJA1) which regulate intercellular communication.

In addition, Src targets cytoskeletal adaptor proteins including AFAP1 and cortactin (CTTN). Phosphorylation of AFAP1 facilitates its binding to the SH2 domain of Src, promoting its localization along actin filaments and influencing cell shape and motility. Cortactin phosphorylation by Src is implicated in the formation of podosomes—actin-rich structures that contribute to invasive cell behavior (agius2019selectiveproteolysisto pages 7-8, joshi2020substratebindingto pages 1-4). Src also phosphorylates RNA-binding proteins such as KHDRBS1, linking its kinase activity to the regulation of pre-mRNA splicing and mRNA processing. Moreover, in the context of signal transduction cascades, Src phosphorylates transcription factors such as STAT1 and STAT3—often in response to PDGF signaling—as well as regulators of the RAS pathway like RASA1 and RASGRF1. Phosphorylation of the clathrin heavy chain (CLTC) by Src at tyrosine 1477 is a well-established modification that modulates epidermal growth factor receptor (EGFR) internalization (agius2019selectiveproteolysisto pages 7-8, johnson2023anatlasof pages 1-2).

Although no universal sequence motif has been defined for Src substrates, studies indicate that the local environment—a combination of flanking hydrophobic or acidic residues and the overall three‐dimensional conformation—is critical for substrate recognition. Once a substrate is phosphorylated, subsequent docking interactions with the Src SH2 domain can further stabilize the interaction, providing additional specificity to the phosphorylation event (joshi2020substratebindingto pages 11-15).

## 5. Structure

Src is organized as a modular protein whose structure underpins its multifaceted regulatory and catalytic functions. The protein architecture consists of several domains that are arranged from the N- to the C-terminus as follows:

• **N-terminal SH4 Domain:**  
At the very N-terminus, Src contains an SH4 domain of approximately 15 amino acids, which is critical for membrane association. This region includes a conserved glycine residue that undergoes N-myristoylation—a lipid modification that permanently attaches a 14-carbon saturated fatty acid to Src. This modification is essential for targeting Src to the plasma membrane and intracellular vesicles, thereby positioning it in the correct locale for receptor-driven activation (li2022srcfamilykinases pages 1-2).

• **Unique Domain:**  
Following the SH4 domain is the unique domain. As its nomenclature implies, this region is variable among the SFK members and is intrinsically disordered. Despite its lack of fixed structure, the unique domain contributes to the fine-tuning of Src’s localization and may mediate specific protein–protein interactions that are key for differential substrate targeting. The functional diversity observed among SFKs is partly attributed to variability in this domain (chakraborty2019targetingdynamicatpbinding pages 9-10).

• **SH3 Domain:**  
The SH3 domain is an approximately 60–amino acid domain that adopts a compact β-barrel fold. It primarily recognizes and binds to proline-rich motifs (PxxP sequences) in target proteins. This domain serves a dual function in Src: it facilitates the recognition of substrates possessing these motifs and, importantly, participates in the autoinhibition of the kinase when bound intramolecularly to the linker region connecting the SH2 and catalytic domains (joshi2020substratebindingto pages 15-17).

• **SH2 Domain:**  
Activated Src also harbors an SH2 domain of roughly 100 amino acids that specifically binds to phosphotyrosine-containing sequences. In the autoinhibited state, the SH2 domain interacts with the phosphorylated C-terminal tail (specifically at Tyr-530 in human Src), thereby locking the protein in a closed, inactive conformation. This intramolecular interaction is a cornerstone of Src regulation, ensuring that kinase activity is suppressed until appropriate extracellular signals are received (agius2019selectiveproteolysisto pages 7-8, joshi2020substratebindingto pages 15-17).

• **Kinase Domain (SH1 Domain):**  
Central to Src’s enzymatic function lies the catalytic kinase domain, also known as the SH1 domain. This domain is structured into two lobes: a smaller N-terminal lobe that predominantly binds and positions ATP and a larger C-terminal lobe that forms the substrate-binding pocket. A highly conserved lysine residue within the N-lobe is crucial for coordinating the phosphate groups of ATP, while conserved aspartate residues aid in catalysis. The activation loop within this domain contains the critical Tyr-416, whose autophosphorylation is a prerequisite for full enzymatic activation (chakraborty2019targetingdynamicatpbinding pages 9-10, boczek2019autophosphorylationactivatescsrc pages 1-2).

• **C-terminal Tail:**  
The C-terminal region of Src contains a short tail that includes a key regulatory tyrosine residue (Tyr-530 in human Src). When phosphorylated by the C-terminal Src kinase (CSK), Tyr-530 engages in an intramolecular interaction with the SH2 domain, enforcing an autoinhibited conformation that prevents open access to the activation loop and substrate-binding region. Dephosphorylation of Tyr-530 is an essential step that permits the kinase domain to adopt an active configuration through subsequent autophosphorylation events (joshi2020substratebindingto pages 15-17, gormal2024locationlocationlocation pages 18-19).

High-resolution X-ray crystallography and recent computational models, including AlphaFold predictions, have provided detailed structural snapshots of both the inactive and active conformations of Src. These models have been instrumental in understanding the dynamic interplay between the regulatory domains and the catalytic core, revealing potential allosteric sites that may be exploited for selective inhibition (berndt2021newstructuralperspectives pages 1-2, joshi2020substratebindingto pages 15-17).

## 6. Regulation

Src activity is finely modulated by a highly interconnected network of regulatory mechanisms that ensure its activation is precisely coordinated with cellular signals. Several layers of regulation are involved:

• **Phosphorylation-Dependent Regulation:**  
 – **Autoinhibitory Phosphorylation (Tyr-530):**  
  Under basal conditions, Src is maintained in an autoinhibited state by phosphorylation of its C-terminal Tyr-530 by CSK. This phosphorylation induces an intramolecular binding of the phosphorylated tail to the SH2 domain, promoting a closed conformation that impedes substrate access to the catalytic site. This autoinhibitory mechanism is pivotal in preventing uncontrolled kinase activity (agius2019selectiveproteolysisto pages 7-8, kumar2015pharmacologyofsrc pages 4-7).  
 – **Activation via Autophosphorylation (Tyr-416):**  
  Upon receptor stimulation and subsequent membrane recruitment, dephosphorylation of Tyr-530 occurs, allowing a conformational change in which the activation loop becomes accessible. Src then undergoes autophosphorylation at Tyr-416 within the kinase domain, a modification that realigns key catalytic residues and stabilizes the active conformation of the kinase (chakraborty2019targetingdynamicatpbinding pages 9-10, boczek2019autophosphorylationactivatescsrc pages 1-2).

• **Intramolecular Domain Interactions:**  
The SH3 and SH2 domains not only mediate substrate interactions but are also critical for intramolecular regulatory binding. In the autoinhibited state, the SH3 domain binds to a proline‐rich linker between the SH2 and catalytic domains, further reinforcing the inactive configuration. Disruption of these interactions—by exogenous ligand binding, mutagenesis, or conformational shifts resulting from receptor engagement—can relieve autoinhibition and promote kinase activation (joshi2020substratebindingto pages 15-17).

• **Receptor-Mediated Recruitment:**  
Engagement of cell surface receptors such as integrins, receptor tyrosine kinases, and G protein-coupled receptors leads to clustering or dimerization events that recruit Src to the plasma membrane. This recruitment, facilitated by the myristoylated SH4 domain, increases the local concentration of Src near its substrates and can induce conformational changes that favor dephosphorylation of Tyr-530 and autophosphorylation of Tyr-416, effectively switching Src from an inactive to an active state (amatya2019dynamicregulatoryfeatures pages 7-9, gormal2024locationlocationlocation pages 18-19).

• **Regulation by Reactive Oxygen Species (ROS):**  
Oxidative stress conditions modulate Src activity indirectly. For instance, ROS influences the phosphorylation status of junctional proteins such as PKP3. Phosphorylation of PKP3 at Tyr-195 in response to ROS can lead to its dissociation from desmosomes, which is part of a broader regulatory cascade that may alter Src localization and activity (agius2019selectiveproteolysisto pages 7-8).

• **Adaptor and Scaffold Protein Interactions:**  
Src interacts with multiple adaptor proteins via its SH2 and SH3 domains. These interactions are essential for integrating signals from various receptors and for assembling multi-protein complexes that dictate the spatial and temporal dynamics of Src-mediated phosphorylation events. Such scaffolding functions not only modulate Src activity but also diversify its downstream signaling outcomes (kumar2015pharmacologyofsrc pages 21-24, joshi2020substratebindingto pages 15-17).

Through these combined regulatory layers, Src acts as a highly responsive molecular switch that can be rapidly turned on or off in response to extracellular cues. This precise regulation is crucial for maintaining cellular homeostasis and for preventing aberrant signaling that might otherwise lead to pathological states (negi2021recentadvancesin pages 12-13, passannanti2021applicationofcomputational pages 111-114).

## 7. Function

Src is a central hub in cellular signaling and plays multifaceted roles in both normal physiology and disease conditions. Its functions span a vast range of biological processes, as detailed below:

• **Signal Transduction:**  
Src is one of the earliest kinases activated following the stimulation of cell surface receptors. Upon receptor engagement and subsequent recruitment to the plasma membrane, Src phosphorylates tyrosine residues on the receptors and on key adaptor proteins. This early phosphorylation event sets into motion downstream signaling cascades, including the activation of MAPK pathways, the PI3K-Akt axis, and the regulation of transcription factors such as STATs. By integrating signals from diverse receptors, Src modulates a wide array of cellular responses including gene expression, cellular metabolism, and cytoskeletal rearrangements (agius2019selectiveproteolysisto pages 7-8, amatya2019dynamicregulatoryfeatures pages 7-9).

• **Cytoskeletal Organization and Cell Adhesion:**  
One of the hallmark functions of Src is its regulation of the cytoskeleton. Src phosphorylates structural and adaptor proteins, such as AFAP1 and cortactin, which are central to the dynamic rearrangement of actin filaments. This regulation is vital for cellular processes such as migration, directional movement, and invasion. Furthermore, Src-mediated phosphorylation of focal adhesion components like FAK and paxillin not only influences cell adhesion to the extracellular matrix but also modulates the formation and turnover of focal adhesions. Similarly, by phosphorylating adherens and gap junction proteins (e.g., beta-catenin, delta-catenin, plakoglobin, and connexin-43), Src influences cell–cell adhesion dynamics and tissue architecture (agius2019selectiveproteolysisto pages 7-8, gormal2024locationlocationlocation pages 18-19).

• **Regulation of Transcription and Pre-mRNA Processing:**  
Beyond its cytoplasmic roles, Src has significant nuclear functions. Through PDGF-mediated pathways, Src phosphorylates transcription factors such as STAT1 and STAT3, thereby promoting their DNA-binding activity and altering gene transcription profiles essential for proliferation and differentiation. Moreover, Src’s phosphorylation of RNA-binding proteins (e.g., KHDRBS1) links it to the regulation of pre-mRNA splicing and processing, suggesting a role in post-transcriptional gene expression regulation that can have broad implications for cell function (agius2019selectiveproteolysisto pages 7-8, negi2021recentadvancesin pages 1-2).

• **Cell Cycle Control and Apoptosis:**  
Src plays an influential role in cell cycle regulation by engaging mitogenic signaling pathways such as the CDK20/MAPK3 cascade, which facilitates progression through different phases of the cell cycle. Additionally, Src modulates apoptotic pathways by phosphorylating key regulators such as caspase-8 at Tyr-380, an event that down-regulates the caspase’s pro-apoptotic function. Through these mechanisms, Src helps coordinate the balance between cell proliferation and programmed cell death, a balance that is often disrupted during oncogenic transformation (joshi2020substratebindingto pages 15-17, kumar2015pharmacologyofsrc pages 7-10).

• **Bone Resorption:**  
In osteoclasts, Src is indispensable for bone resorption. Src forms complexes with kinases such as PTK2B/PYK2 and phosphorylates substrates like CBL to recruit phosphatidylinositol 3-kinase (PI3K). This signaling cascade not only triggers the resorptive activity of osteoclasts but also stimulates mitochondrial energy production via cytochrome C oxidase activation, thereby fulfilling the considerable energetic demands required for bone remodeling (ma2019characterizationofthe pages 1-2, martellucci2020srcfamilykinases pages 18-20).

• **Regulation of Receptor Internalization and Desensitization:**  
Src contributes to the internalization of receptors through phosphorylation-dependent mechanisms. For example, phosphorylation of clathrin heavy chain (CLTC) at Tyr-1477 by Src is essential for EGFR internalization, a process that facilitates receptor recycling or degradation following ligand binding. Concurrently, Src regulates β-arrestin desensitization through the activation of GRK2, ensuring that receptor signaling is appropriately tempered after activation (johnson2023anatlasof pages 1-2, amatya2019dynamicregulatoryfeatures pages 7-9).

• **Immune and Antiviral Signaling:**  
Src has been implicated in various aspects of immune signaling. By enhancing RIG-I-mediated antiviral responses, Src participates in the cellular innate immune defense against viral infection. Additionally, Src is known to influence inflammatory signaling pathways—such as the IL6–YAP1–NOTCH cascade—which promote epithelial regeneration in response to tissue injury. These roles position Src as a key intermediary not only in normal immune responses but also in pathological states such as chronic inflammation (agius2019selectiveproteolysisto pages 7-8, gormal2024locationlocationlocation pages 18-19).

Collectively, the wide range of Src functions underscores its importance as an integrator of extracellular signals, translating them into diverse cellular outcomes that include changes in gene expression, morphology, adhesion, and survival. Its ability to cross-communicate between cytoplasmic and nuclear events further exemplifies the versatility and centrality of Src in cellular physiology (amatya2019dynamicregulatoryfeatures pages 7-9, joshi2020substratebindingto pages 1-4, fischer2017approvedandexperimental pages 24-27).

## 8. Other Comments

In addition to its well-established catalytic and regulatory roles, Src is also notable for several extra-catalytic functions and associations that have broad implications in both basic research and clinical applications:

• **Inhibitors and Therapeutic Targeting:**  
Src’s involvement in multiple signaling pathways and its hyperactivation in various cancers make it a prime target for therapeutic intervention. A significant number of small-molecule inhibitors, primarily targeting the ATP-binding pocket of the kinase domain, have been developed. However, achieving selectivity for Src over other SFKs is challenging due to high structural homology. Emerging approaches include allosteric inhibitors and substrate-based inhibitors, which aim to exploit unique conformational or docking interfaces to enhance selectivity and reduce off-target effects (biswas2024theprospectof pages 1-2, chakraborty2019targetingdynamicatpbinding pages 9-10).

• **Functional Redundancy and Compensatory Mechanisms:**  
While Src is often the principal kinase activated downstream of receptor engagement, it exists within a family of closely related kinases that can compensate for one another’s loss or inhibition. This functional redundancy presents both a challenge and an opportunity; understanding the unique versus overlapping roles of SFKs is critical for designing effective therapies. Advanced phosphoproteomic studies and genetic models are currently being utilized to delineate Src-specific functions from those shared by other SFK members (agius2019selectiveproteolysisto pages 7-8, amatya2019dynamicregulatoryfeatures pages 7-9).

• **Disease Associations:**  
Aberrant Src signaling has been implicated in a variety of disease states. In oncology, elevated Src activity correlates with tumor progression, metastasis, and therapy resistance in cancers such as breast, colon, lung, and pancreatic carcinoma. In the skeletal system, mutations or dysregulation of Src are associated with osteoclast dysfunction, contributing to bone disorders like osteopetrosis. There is also growing evidence linking Src dysregulation to inflammation and immune deficiencies, as well as emerging associations with neurodegenerative conditions where disturbances in cellular adhesion and signaling are present (goel2023seekingabetter pages 1-2, kumar2015pharmacologyofsrc pages 7-10).

• **Drug Resistance and Combination Therapies:**  
Clinical investigations of Src inhibitors have uncovered challenges related to drug resistance. Often, the inhibition of Src alone is insufficient to produce durable responses in cancer, as compensatory activation of alternative pathways can circumvent the block. As a result, combination therapies that target Src in conjunction with other signaling nodes (such as PI3K-Akt or MAPK pathways) are being explored. These combination strategies aim to reduce the likelihood of resistance and to produce synergistic antitumor effects (biswas2024theprospectof pages 1-2, chakraborty2019targetingdynamicatpbinding pages 9-10).

• **Scaffolding and Non-Catalytic Roles:**  
In addition to its enzymatic activity, Src functions as an adaptor or scaffolding protein via its SH2 and SH3 domains. These domains mediate the assembly of large multiprotein complexes, thereby extending Src’s influence beyond direct phosphorylation events. The ability to function in a scaffolding capacity is critical for the fine-tuning of signal transduction networks, as it helps organize signaling complexes at discrete cellular locations (joshi2020substratebindingto pages 1-4, ortiz2021srcfamilykinases pages 2-5).

• **Current Research Trends:**  
The current research landscape on Src focuses on obtaining high-resolution structural insights and dynamic models that explain how Src transitions between different conformational states. Computational modeling and molecular dynamics simulations are increasingly used to predict allosteric changes and to aid in the design of next-generation inhibitors. Such studies are vital for developing agents with greater specificity and improved clinical profiles. Additionally, the role of Src in regulating not only cytoplasmic but also nuclear events is receiving renewed attention, with implications for how aberrant Src activation contributes to transcriptional dysregulation in disease (passannanti2021applicationofcomputational pages 111-114, negi2021recentadvancesin pages 1-2).

These additional features highlight that Src is not simply a conventional enzyme but a multifunctional signaling hub whose disruption can lead to significant pathological consequences. Its central position within the cellular signaling network and its involvement in multiple disease processes underscore the importance of continued research into the development of targeted, selective inhibitors.

## 9. References

agius2019selectiveproteolysisto pages 7-8, amatya2019dynamicregulatoryfeatures pages 7-9, biswas2024theprospectof pages 1-2, bradley2019evolutionofprotein pages 1-2, cabail2016autothiophosphorylationactivityof pages 10-10, chakraborty2019targetingdynamicatpbinding pages 9-10, fischer2017approvedandexperimental pages 24-27, goel2023seekingabetter pages 1-2, gormal2024locationlocationlocation pages 18-19, johnson2023anatlasof pages 1-2, joshi2020substratebindingto pages 1-4, joshi2020substratebindingto pages 11-15, joshi2020substratebindingto pages 15-17, kumar2015pharmacologyofsrc pages 1-4, kumar2015pharmacologyofsrc pages 10-13, kumar2015pharmacologyofsrc pages 21-24, kumar2015pharmacologyofsrc pages 4-7, kumar2015pharmacologyofsrc pages 7-10, li2022srcfamilykinases pages 1-2, luo2022srckinasemediatedsignaling pages 1-2, ma2019characterizationofthe pages 1-2, martellucci2020srcfamilykinases pages 18-20, min2022crosstalkbetweenwnt pages 23-24, mohanty2016hydrophobiccorevariations pages 21-23, negi2021recentadvancesin pages 1-2, negi2021recentadvancesin pages 12-13, passannanti2021applicationofcomputational pages 11-14, passannanti2021applicationofcomputational pages 111-114, ortiz2021srcfamilykinases pages 1-2, ortiz2021srcfamilykinases pages 2-5.

References

1. (agius2019selectiveproteolysisto pages 7-8): Michael P. Agius, Kristin S. Ko, Taylor K. Johnson, Frank E. Kwarcinski, Sameer Phadke, Eric J. Lachacz, and Matthew B. Soellner. Selective proteolysis to study the global conformation and regulatory mechanisms of c-src kinase. ACS Chemical Biology, 14:1556-1563, Jun 2019. URL: https://doi.org/10.1021/acschembio.9b00306, doi:10.1021/acschembio.9b00306. This article has 19 citations and is from a domain leading peer-reviewed journal.
2. (amatya2019dynamicregulatoryfeatures pages 7-9): Neha Amatya, David Yin-wei Lin, and Amy H. Andreotti. Dynamic regulatory features of the protein tyrosine kinases. Biochemical Society Transactions, 47:1101-1116, Aug 2019. URL: https://doi.org/10.1042/bst20180590, doi:10.1042/bst20180590. This article has 31 citations and is from a peer-reviewed journal.
3. (berndt2021newstructuralperspectives pages 1-2): Sandra Berndt and Ines Liebscher. New structural perspectives in g protein-coupled receptor-mediated src family kinase activation. International Journal of Molecular Sciences, Jun 2021. URL: https://doi.org/10.3390/ijms22126489, doi:10.3390/ijms22126489. This article has 21 citations and is from a peer-reviewed journal.
4. (biswas2024theprospectof pages 1-2): Biswajit Biswas, Yen-Hua Huang, David J. Craik, and Conan K. Wang. The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance. Chemical Science, 15:13130-13147, Jul 2024. URL: https://doi.org/10.1039/d4sc01088d, doi:10.1039/d4sc01088d. This article has 2 citations and is from a highest quality peer-reviewed journal.
5. (boczek2019autophosphorylationactivatescsrc pages 1-2): Edgar E. Boczek, Qi Luo, Marco Dehling, Michael Röpke, Sophie L. Mader, Andreas Seidl, Ville R.I. Kaila, and Johannes Buchner. Autophosphorylation activates c-src kinase through global structural rearrangements. Journal of Biological Chemistry, 294:13186-13197, Aug 2019. URL: https://doi.org/10.1074/jbc.ra119.008199, doi:10.1074/jbc.ra119.008199. This article has 24 citations and is from a domain leading peer-reviewed journal.
6. (bradley2019evolutionofprotein pages 1-2): David Bradley and Pedro Beltrao. Evolution of protein kinase substrate recognition at the active site. PLOS Biology, 17:e3000341, Jun 2019. URL: https://doi.org/10.1371/journal.pbio.3000341, doi:10.1371/journal.pbio.3000341. This article has 75 citations and is from a highest quality peer-reviewed journal.
7. (cabail2016autothiophosphorylationactivityof pages 10-10): M. Zulema Cabail, Emily I. Chen, Antonius Koller, and W. Todd Miller. Auto-thiophosphorylation activity of src tyrosine kinase. BMC Biochemistry, Jul 2016. URL: https://doi.org/10.1186/s12858-016-0071-z, doi:10.1186/s12858-016-0071-z. This article has 6 citations and is from a peer-reviewed journal.
8. (chakraborty2019targetingdynamicatpbinding pages 9-10): Sujata Chakraborty, Takayuki Inukai, Linglan Fang, Martin Golkowski, and Dustin J. Maly. Targeting dynamic atp-binding site features allows discrimination between highly homologous protein kinases. ACS Chemical Biology, 14:1249-1259, Apr 2019. URL: https://doi.org/10.1021/acschembio.9b00214, doi:10.1021/acschembio.9b00214. This article has 29 citations and is from a domain leading peer-reviewed journal.
9. (fischer2017approvedandexperimental pages 24-27): Peter M. Fischer. Approved and experimental small‐molecule oncology kinase inhibitor drugs: a mid‐2016 overview. Medicinal Research Reviews, Mar 2017. URL: https://doi.org/10.1002/med.21409, doi:10.1002/med.21409. This article has 103 citations and is from a domain leading peer-reviewed journal.
10. (goel2023seekingabetter pages 1-2): Raghuveera Kumar Goel, Nayoung Kim, and Kiven Erique Lukong. Seeking a better understanding of the non-receptor tyrosine kinase, srms. Heliyon, 9:e16421, Jun 2023. URL: https://doi.org/10.1016/j.heliyon.2023.e16421, doi:10.1016/j.heliyon.2023.e16421. This article has 2 citations and is from a peer-reviewed journal.
11. (gormal2024locationlocationlocation pages 18-19): Rachel S Gormal, Ramon Martinez-Marmol, Andrew J Brooks, and Frédéric A Meunier. Location, location, location: protein kinase nanoclustering for optimised signalling output. eLife, Jan 2024. URL: https://doi.org/10.7554/elife.93902, doi:10.7554/elife.93902. This article has 11 citations and is from a domain leading peer-reviewed journal.
12. (johnson2023anatlasof pages 1-2): Jared L. Johnson, Tomer M. Yaron, Emily M. Huntsman, Alexander Kerelsky, Junho Song, Amit Regev, Ting-Yu Lin, Katarina Liberatore, Daniel M. Cizin, Benjamin M. Cohen, Neil Vasan, Yilun Ma, Konstantin Krismer, Jaylissa Torres Robles, Bert van de Kooij, Anne E. van Vlimmeren, Nicole Andrée-Busch, Norbert F. Käufer, Maxim V. Dorovkov, Alexey G. Ryazanov, Yuichiro Takagi, Edward R. Kastenhuber, Marcus D. Goncalves, Benjamin D. Hopkins, Olivier Elemento, Dylan J. Taatjes, Alexandre Maucuer, Akio Yamashita, Alexei Degterev, Mohamed Uduman, Jingyi Lu, Sean D. Landry, Bin Zhang, Ian Cossentino, Rune Linding, John Blenis, Peter V. Hornbeck, Benjamin E. Turk, Michael B. Yaffe, and Lewis C. Cantley. An atlas of substrate specificities for the human serine/threonine kinome. Nature, 613:759-766, Jan 2023. URL: https://doi.org/10.1038/s41586-022-05575-3, doi:10.1038/s41586-022-05575-3. This article has 416 citations and is from a highest quality peer-reviewed journal.
13. (joshi2020substratebindingto pages 1-4): Mehul K. Joshi, Robert A. Burton, Heng Wu, Andrew M. Lipchik, Barbara P. Craddock, Huaping Mo, Laurie L. Parker, W. Todd Miller, and Carol Beth Post. Substrate binding to src: a new perspective on tyrosine kinase substrate recognition from nmr and molecular dynamics. Protein Science, 29:350-359, Nov 2020. URL: https://doi.org/10.1002/pro.3777, doi:10.1002/pro.3777. This article has 14 citations and is from a peer-reviewed journal.
14. (joshi2020substratebindingto pages 11-15): Mehul K. Joshi, Robert A. Burton, Heng Wu, Andrew M. Lipchik, Barbara P. Craddock, Huaping Mo, Laurie L. Parker, W. Todd Miller, and Carol Beth Post. Substrate binding to src: a new perspective on tyrosine kinase substrate recognition from nmr and molecular dynamics. Protein Science, 29:350-359, Nov 2020. URL: https://doi.org/10.1002/pro.3777, doi:10.1002/pro.3777. This article has 14 citations and is from a peer-reviewed journal.
15. (joshi2020substratebindingto pages 15-17): Mehul K. Joshi, Robert A. Burton, Heng Wu, Andrew M. Lipchik, Barbara P. Craddock, Huaping Mo, Laurie L. Parker, W. Todd Miller, and Carol Beth Post. Substrate binding to src: a new perspective on tyrosine kinase substrate recognition from nmr and molecular dynamics. Protein Science, 29:350-359, Nov 2020. URL: https://doi.org/10.1002/pro.3777, doi:10.1002/pro.3777. This article has 14 citations and is from a peer-reviewed journal.
16. (kumar2015pharmacologyofsrc pages 1-4): Amit Kumar, Amteshwar S. Jaggi, and Nirmal Singh. Pharmacology of src family kinases and therapeutic implications of their modulators. Fundamental & Clinical Pharmacology, Apr 2015. URL: https://doi.org/10.1111/fcp.12097, doi:10.1111/fcp.12097. This article has 55 citations.
17. (kumar2015pharmacologyofsrc pages 10-13): Amit Kumar, Amteshwar S. Jaggi, and Nirmal Singh. Pharmacology of src family kinases and therapeutic implications of their modulators. Fundamental & Clinical Pharmacology, Apr 2015. URL: https://doi.org/10.1111/fcp.12097, doi:10.1111/fcp.12097. This article has 55 citations.
18. (kumar2015pharmacologyofsrc pages 21-24): Amit Kumar, Amteshwar S. Jaggi, and Nirmal Singh. Pharmacology of src family kinases and therapeutic implications of their modulators. Fundamental & Clinical Pharmacology, Apr 2015. URL: https://doi.org/10.1111/fcp.12097, doi:10.1111/fcp.12097. This article has 55 citations.
19. (kumar2015pharmacologyofsrc pages 4-7): Amit Kumar, Amteshwar S. Jaggi, and Nirmal Singh. Pharmacology of src family kinases and therapeutic implications of their modulators. Fundamental & Clinical Pharmacology, Apr 2015. URL: https://doi.org/10.1111/fcp.12097, doi:10.1111/fcp.12097. This article has 55 citations.
20. (kumar2015pharmacologyofsrc pages 7-10): Amit Kumar, Amteshwar S. Jaggi, and Nirmal Singh. Pharmacology of src family kinases and therapeutic implications of their modulators. Fundamental & Clinical Pharmacology, Apr 2015. URL: https://doi.org/10.1111/fcp.12097, doi:10.1111/fcp.12097. This article has 55 citations.
21. (li2022srcfamilykinases pages 1-2): Nannan Li, Guoxin Lin, Hao Zhang, Jian Sun, Ming Gui, Yan Liu, Wei Li, Jishi Liu, and Juan Tang. Src family kinases: a potential therapeutic target for acute kidney injury. Biomolecules, 12:984, Jul 2022. URL: https://doi.org/10.3390/biom12070984, doi:10.3390/biom12070984. This article has 24 citations and is from a peer-reviewed journal.
22. (luo2022srckinasemediatedsignaling pages 1-2): Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Liping Ye, Chengming Zhu, Liang Deng, Bo Wang, Yihang Pan, and Peng Li. Src kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Research, Dec 2022. URL: https://doi.org/10.1186/s13058-022-01596-y, doi:10.1186/s13058-022-01596-y. This article has 77 citations and is from a domain leading peer-reviewed journal.
23. (ma2019characterizationofthe pages 1-2): Xiuquan Ma, Luxi Zhang, Jiangning Song, Elizabeth V. Nguyen, Rachel S. Lee, S. Rodgers, Fuyi Li, Cheng Huang, R. Schittenhelm, Howard C. Chan, Chanly Chheang, Jianmin Wu, K. Brown, C. Mitchell, K. Simpson, and R. Daly. Characterization of the src-regulated kinome identifies sgk1 as a key mediator of src-induced transformation. Nature Communications, Jan 2019. URL: https://doi.org/10.1038/s41467-018-08154-1, doi:10.1038/s41467-018-08154-1. This article has 33 citations and is from a highest quality peer-reviewed journal.
24. (martellucci2020srcfamilykinases pages 18-20): Stefano Martellucci, Letizia Clementi, Samantha Sabetta, Vincenzo Mattei, Lorenzo Botta, and Adriano Angelucci. Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers, 12:1448, Jun 2020. URL: https://doi.org/10.3390/cancers12061448, doi:10.3390/cancers12061448. This article has 133 citations and is from a peer-reviewed journal.
25. (min2022crosstalkbetweenwnt pages 23-24): Jung Ki Min, Hwee-Seon Park, Yoon-Beom Lee, Jae-Gyu Kim, Jong-Il Kim, and Jae-Bong Park. Cross-talk between wnt signaling and src tyrosine kinase. Biomedicines, 10:1112, May 2022. URL: https://doi.org/10.3390/biomedicines10051112, doi:10.3390/biomedicines10051112. This article has 20 citations and is from a peer-reviewed journal.
26. (mohanty2016hydrophobiccorevariations pages 21-23): Smita Mohanty, Krishnadev Oruganty, Annie Kwon, Dominic P. Byrne, Samantha Ferries, Zheng Ruan, Laura E. Hanold, Samiksha Katiyar, Eileen J. Kennedy, Patrick A. Eyers, and Natarajan Kannan. Hydrophobic core variations provide a structural framework for tyrosine kinase evolution and functional specialization. PLOS Genetics, 12:e1005885, Feb 2016. URL: https://doi.org/10.1371/journal.pgen.1005885, doi:10.1371/journal.pgen.1005885. This article has 42 citations and is from a domain leading peer-reviewed journal.
27. (negi2021recentadvancesin pages 1-2): Preeya Negi, Rameshwar S. Cheke, and Vaishali M. Patil. Recent advances in pharmacological diversification of src family kinase inhibitors. Egyptian Journal of Medical Human Genetics, Jun 2021. URL: https://doi.org/10.1186/s43042-021-00172-x, doi:10.1186/s43042-021-00172-x. This article has 22 citations and is from a peer-reviewed journal.
28. (negi2021recentadvancesin pages 12-13): Preeya Negi, Rameshwar S. Cheke, and Vaishali M. Patil. Recent advances in pharmacological diversification of src family kinase inhibitors. Egyptian Journal of Medical Human Genetics, Jun 2021. URL: https://doi.org/10.1186/s43042-021-00172-x, doi:10.1186/s43042-021-00172-x. This article has 22 citations and is from a peer-reviewed journal.
29. (ortiz2021srcfamilykinases pages 1-2): Maria A. Ortiz, Tatiana Mikhailova, Xiang Li, Baylee A. Porter, Alaji Bah, and Leszek Kotula. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Communication and Signaling, Jun 2021. URL: https://doi.org/10.1186/s12964-021-00750-x, doi:10.1186/s12964-021-00750-x. This article has 129 citations and is from a peer-reviewed journal.
30. (ortiz2021srcfamilykinases pages 2-5): Maria A. Ortiz, Tatiana Mikhailova, Xiang Li, Baylee A. Porter, Alaji Bah, and Leszek Kotula. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Communication and Signaling, Jun 2021. URL: https://doi.org/10.1186/s12964-021-00750-x, doi:10.1186/s12964-021-00750-x. This article has 129 citations and is from a peer-reviewed journal.
31. (passannanti2021applicationofcomputational pages 11-14): R Passannanti. Application of computational methods for the design and optimization of src family kinase inhibitors. Unknown journal, 2021.
32. (passannanti2021applicationofcomputational pages 111-114): R Passannanti. Application of computational methods for the design and optimization of src family kinase inhibitors. Unknown journal, 2021.